文献速递脑血管病

替奈普酶与阿替普酶治疗4.5小时内急性缺血性卒中:随机试验的系统综述与Meta分析

Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours: A Systematic Review and Meta-Analysis of Randomized Trials.
PubMed 文献 · Neurology · 2024-10-16

该系统综述与Meta分析纳入11项随机对照试验,比较替奈普酶0.25 mg/kg与阿替普酶治疗4.5小时内急性缺血性卒中的疗效与安全性。替奈普酶组3个月极佳功能结局(改良Rankin量表评分0-1)和残疾减轻优于阿替普酶组,良好功能结局、症状性颅内出血和3个月死亡率两组相似。

要点

  • 替奈普酶0.25 mg/kg组3个月极佳功能结局优于阿替普酶组(RR 1.05,95%CI 1.01-1.10)。
  • 替奈普酶组3个月残疾减轻优于阿替普酶组(共同比值比1.10,95%CI 1.01-1.19)。
  • 两组症状性颅内出血和3个月死亡率相似,安全性相当。

核心结论

  • 更新的Meta分析证实替奈普酶0.25 mg/kg与阿替普酶安全性相似,而替奈普酶在3个月极佳功能结局和残疾减轻方面优于阿替普酶。
  • 这些发现支持在临床实践中转向使用替奈普酶。

研究设计与样本

  • 系统综述与Meta分析,纳入所有比较替奈普酶0.25 mg/kg与阿替普酶治疗发病4.5小时内急性缺血性卒中的随机对照试验。
  • 共纳入11项随机对照试验,替奈普酶组3788例,阿替普酶组3757例。
  • 采用随机效应模型计算合并估计值,并预设亚组分析按替奈普酶制剂(原研 vs 生物类似药)分层。

主要发现

  • 替奈普酶组3个月极佳功能结局(改良Rankin量表评分0-1)高于阿替普酶组(RR 1.05,95%CI 1.01-1.10;p=0.012;I²=0%;风险差2.95%,95%CI 0.76%-5.14%;p=0.008;I²=0%)。
  • 替奈普酶组3个月残疾减轻优于阿替普酶组(共同比值比1.10,95%CI 1.01-1.19;p=0.034;I²=0%)。
  • 两组3个月良好功能结局(改良Rankin量表评分0-2)相似(RR 1.03,95%CI 0.99-1.07;p=0.142;I²=28%)。
  • 两组症状性颅内出血发生率相似(RR 1.12,95%CI 0.83-1.53;p=0.456;I²=0%)和3个月死亡率相似(RR 0.97,95%CI 0.82-1.15;p=0.727;I²=12%)。
  • 按替奈普酶制剂分层后,原研替奈普酶组3个月极佳功能结局的统计学显著性仍保留(RR 1.05,95%CI 1.00-1.10;p=0.044;I²=0%)。

关键数值与推荐

  • 欧洲卒中组织快速推荐:替奈普酶0.25 mg/kg可作为阿替普酶的替代用于发病4.5小时内急性缺血性卒中,基于Meta分析方法确立非劣效性。

临床怎么用

  • 作者认为这些发现支持在临床实践中转向使用替奈普酶。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The current European Stroke Organisation expedited recommendation on tenecteplase (TNK) for acute ischemic stroke (AIS) advocates that TNK 0.25 mg/kg can be used alternatively to alteplase (tissue plasminogen activator [TPA]) for AIS of <4.5 hours duration, based on a meta-analytical approach establishing noninferiority. Since the publication of these guidelines, 4 additional randomized controlled clinical trials (RCTs) have provided further insight. METHODS: We conducted an updated systematic review and meta-analysis including all available RCTs that investigated efficacy and safety of TNK 0.25 mg/kg compared with TPA for the treatment of AIS within 4.5 hours of onset. The primary outcome was defined as the excellent functional outcome at 3 months (modified Rankin Scale [mRS] score 0-1), whereas good functional outcome (mRS score 0-2), reduced disability at 3 months (≥1-point reduction across all mRS scores), symptomatic intracranial hemorrhage (sICH), and 3-month mortality were evaluated as secondary outcomes. Pooled estimates were calculated with random-effects model. A prespecified subgroup analysis was performed stratifying for TNK formulation, that is, original TNK vs biocopy: recombinant human TNK tissue-type plasminogen activator that is available in China and has a different production process. RESULTS: Eleven RCTs were included comprising a total of 3,788 patients treated with TNK vs 3,757 patients treated with TPA. TNK was associated with higher likelihood of excellent functional outcome (risk ratio [RR] 1.05, 95% CI 1.01-1.10; p = 0.012; I2 = 0%; risk difference 2.95%; 95% CI 0.76%-5.14%; p = 0.008; I2 = 0%) and reduced disability at 3 months (common odds ratio 1.10, 95% CI 1.01-1.19; p = 0.034; I2 = 0%) compared with TPA while good functional outcome (RR 1.03, 95% CI 0.99-1.07; p = 0.142; I2 = 28%) was similar between the groups. Regarding safety outcomes, similar rates of sICH (RR 1.12, 95% CI 0.83-1.53; p = 0.456; I2 = 0%) and 3-month mortality (RR 0.97, 95% CI 0.82-1.15; p = 0.727; I2 = 12%) were observed. When stratified for TNK regimen (original vs biocopy), statistical significance in achieving an excellent functional outcome at 3 months was retained for the original TNK (RR 1.05, 95% CI 1.00-1.10; p = 0.044; I2 = 0%). DISCUSSION: The updated meta-analysis confirms similar safety between TNK 0.25 mg/kg and TPA, while showing that TNK is superior to TPA regarding excellent functional outcome and reduced disability at 3 months. These findings support transitioning to TNK in clinical practice.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Palaiodimou L, Katsanos AH, Turc G, et al. Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours: A Systematic Review and Meta-Analysis of Randomized Trials. Neurology. 2024. PMID: 39413337. doi:10.1212/WNL.0000000000209903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。